Search

Your search keyword '"Giuily, Nathalie"' showing total 24 results
Start Over Author "Giuily, Nathalie"
24 results on '"Giuily, Nathalie"'

1. Early hepatocellular carcinoma detection using magnetic resonance imaging is cost-effective in high-risk patients with cirrhosis

Author

Nahon, Pierre, Asselah, Tarik, Guyader, Dominique, Pol, Stanislas, Fontaine, Hélène, Pageaux, Georges-Philippe, De Lédinghen, Victor, Ouzan, Denis, Zoulim, Fabien, Roulot, Dominique, Tran, Albert, Bronowicki, Jean-Pierre, Decaensi, Thomas, Riachi, Ghassan, Calès, Paul, Péron, Jean-Marie, Alric, Laurent, Bourlière, Marc, Mathurin, Philippe, Dharancy, Sebastien, Blanc, Jean-Frédéric, Abergel, Armand, Chazouillères, Olivier, Mallat, Ariane, Grangé, Jean-Didier, Attali, Pierre, d’Alteroche, Louis, Wartelle, Claire, Dao, Thông, Thabut, Dominique, Pilette, Christophe, Silvain, Christine, Christidis, Christos, Nguyen-Khac, Eric, Bernard-Chabert, Brigitte, Hillaire, Sophie, Di Martino, Vincent, Bonnet, Delphine, Payssan-Sicart, Virginie, Pomes, Chloe, Bailly, François, Beaudoin, Marjolaine, Giboz, Dominique, Hartig-Lavie, Kerstin, Maynard, Marianne, Billaud, Eric, Boutoille, David, Cavellec, Morane, Cheraud-Carpentier, Marjorie, Hubert, Isabelle, Benhida, Jaouad, Lannes, Adrien, Lunel, Françoise, Oberti, Frédéric, Boyer, Nathalie, Giuily, Nathalie, Castelnau, Corinne, Scoazec, Giovanna, Chibah, Aziza, Keser, Sylvie, Bonardi, Karim, Vallet-Pichard, Anaïs, Sogni, Philippe, Foucher, Juliette, Hiriart, Jean-Baptiste, Wilson, Amy, Shili, Sarah, Chermak, Faiza, Ansaldi, Christelle, Ben Amara, Nisserine, Chouquet, Laëtitia, De Luca, Emilie, Oules, Valérie, Anty, Rodolphe, Gelsi, Eve, Truchi, Régine, Luckina, Elena, Messaoudi, Nadia, Moussali, Joseph, De Dieuleveult, Barbara, Labarriere, Damien, Poter, Pascal, Si Ahmed, Si Nafa, Grando-Lemaire, Véronique, Bourcier, Valérie, Brulé, Séverine, Stalhberger, Thomas, Jezequel, Caroline, Brener, Audrey, Laligant, Anne, Rabot, Aline, Renard, Isabelle, Baumert, Thomas F., Dofföel, Michel, Mutter, Catherine, Simo-Noumbissie, Pauline, Razi, Esma, Barraud, Hélène, Bensenane, Mouni, Nani, Abdelbasset, Hassani-Nani, Sarah, Bernard, Marie-Albertine, Bismuth, Michael, Caillo, Ludovic, Faure, Stéphanie, Ripault, Marie Pierre, Bureau, Christophe, Peron, Jean Marie, Robic, Marie Angèle, Tarallo, Léa, Faure, Marine, Froissart, Bruno, Hilleret, Marie-Noelle, Zarski, Jean-Pierre, Goria, Odile, Grard, Victorien, Montialoux, Hélène, François, Muriel, Ouedraogo, Christian, Pauleau, Christelle, Varault, Anne, Andreani, Tony, Angoulevant, Bénédicte, Chevance, Azeline, Serfaty, Lawrence, Antonini, Teresa, Coilly, Audrey, Duclos Vallée, Jean-Charles, Tateo, Mariagrazia, Bonny, Corinne, Brigitte, Chanteranne, Lamblin, Géraldine, Muti, Léon, Babouri, Abdenour, Filipe, Virginie, Barrault, Camille, Costes, Laurent, Hagège, Hervé, Merbah, Soraya, Carrier, Paul, Debette-Gratien, Maryline, Jacques, Jérémie, Lassailly, Guillaume, Artu, Florent, Canva, Valérie, Dharancy, Sébastien, Louvet, Alexandre, Latournerie, Marianne, Bardou, Marc, Mouillot, Thomas, Bacq, Yannick, Barbereau, Didier, Nicolas, Charlotte, Chevalier, Caroline, Archambeaud, Isabelle, Habes, Sarah, Botta-Fridlund, Danièle, Saillard, Eric, Lafrance, Marie-Josée, Cacoub, Patrice, Carrat, Fabrice, Carrieri, Patrizia, Delarocque-Astagneau, Elisabeth, De Ledinghen, Victor, Dorival, Céline, Dubuisson, Jean, Housset, Chantal, Larrey, Dominique, Marcellin, Patrick, Pawlotsky, Jean-Michel, Petrov-Sanchez, Ventzislava, Vaux, Sophie, Wittkop, Linda, Yazdanpanah, Yazdan, Zucman-Rossi, Jessica, Ganne-Carrié, Nathalie, Chaffaut, Cendrine, Moreno, Christophe, Moirand, Romain, Carbonell, Nicolas, Duclos-Vallée, Jean-Charles, de Ledinghen, Victor, Ozenne, Violaine, Henrion, Jean, Perlemuter, Gabriel, Amiot, Xavier, Chevret, Sylvie, Najean, Marie, Layese, Richard, Zarca, Kevin, Segar, Laeticia Blampain, Cagnot, Carole, N’Kontchou, Gisèle, Ronot, Maxime, Audureau, Etienne, and Durand-Zaleski, Isabelle

Published
2022
Full Text
View/download PDF

2. Absence of impact of direct acting antivirals for hepatitis C virus on recurrent hepatocellular carcinoma tumor growth in the AFEF/ANRS CO22 Hepather cohort

Author

Bonnet, Delphine, Payssan-Sicart, Virginie, Pomes, Chloe, Bailly, François, Beaudoin, Marjolaine, Giboz, Dominique, Hartig-Lavie, Kerstin, Maynard, Marianne, Billaud, Eric, Boutoille, David, Cavellec, Morane, Cheraud-Carpentier, Marjorie, Hubert, Isabelle, Benhida, Jaouad, Lannes, Adrien, Lunel, Françoise, Oberti, Frédéric, Boyer, Nathalie, Giuily, Nathalie, Castelnau, Corinne, Scoazec, Giovanna, Chibah, Aziza, Keser, Sylvie, Bonardi, Karim, Vallet-Pichard, Anaïs, Sogni, Philippe, Foucher, Juliette, Hiriart, Jean-Baptiste, Wilson, Amy, Shili, Sarah, Chermak, Faiza, Ansaldi, Christelle, Amara, Nisserine Ben, Chouquet, Laëtitia, De Luca, Emilie, Oules, Valérie, Anty, Rodolphe, Gelsi, Eve, Truchi, Régine, Luckina, Elena, Messaoudi, Nadia, Moussali, Joseph, De Dieuleveult, Barbara, Labarriere, Damien, Poter, Pascal, Ahmed, Si Nafa Si, Grando-Lemaire, Véronique, Nahon, Pierre, Bourcier, Valérie, Brulé, Séverine, Stalhberger, Thomas, Jezequel, Caroline, Brener, Audrey, Laligant, Anne, Rabot, Aline, Renard, Isabelle, Baumert, Thomas F., Dofföel, Michel, Mutter, Catherine, Simo-Noumbissie, Pauline, Razi, Esma, Barraud, Hélène, Bensenane, Mouni, Nani, Abdelbasset, Hassani-Nani, Sarah, Bernard, Marie-Albertine, Pageaux, Georges-Philippe, Bismuth, Michael, Caillo, Ludovic, Faure, Stéphanie, Ripault, Marie-Pierre, Bureau, Christophe, Peron, Jean Marie, Robic, Marie-Angèle, Tarallo, Léa, Faure, Marine, Froissart, Bruno, Hilleret, Marie-Noelle, Zarski, Jean-Pierre, Goria, Odile, Grard, Victorien, Montialoux, Hélène, François, Muriel, Ouedraogo, Christian, Pauleau, Christelle, Varault, Anne, Andreani, Tony, Angoulevant, Bénédicte, Chevance, Azeline, Serfaty, Lawrence, Antonini, Teresa, Coilly, Audrey, Vallée, Jean-Charles Duclos, Tateo, Mariagrazia, Bonny, Corinne, Brigitte, Chanteranne, Lamblin, Géraldine, Muti, Léon, Babouri, Abdenour, Filipe, Virginie, Barrault, Camille, Costes, Laurent, Hagège, Hervé, Merbah, Soraya, Carrier, Paul, Debette-Gratien, Maryline, Jacques, Jérémie, Lassailly, Guillaume, Artu, Florent, Canva, Valérie, Dharancy, Sébastien, Louvet, Alexandre, Latournerie, Marianne, Bardou, Marc, Mouillot, Thomas, Bacq, Yannick, Barbereau, Didier, Nicolas, Charlotte, Chevalier, Caroline, Archambeaud, Isabelle, Habes, Sarah, Botta-Fridlund, Danièle, Saillard, Eric, Lafrance, Marie-Josée, Vallet-Pichard, Anais, Correas, Jean-Michel, Dorival, Celine, Zoulim, Fabien, Tran, Albert, Bourlière, Marc, Calès, Paul, Guyader, Dominique, Bronowicki, Jean-Pierre, Larrey, Dominique, Hezode, Christophe, Loustaud-Ratti, Veronique, Gournay, Jerome, de Ledinghen, Victor, Asselah, Tarik, Ganne, Nathalie, Metivier, Sophie, Chazouillères, Olivier, Leroy, Vincent, Rosa, Isabelle, Samuel, Didier, Mathurin, Philippe, Cagnot, Carole, Fontaine, Helene, Carrat, Fabrice, and Pol, Stanislas

Published
2021
Full Text
View/download PDF

3. Cannabis use as a factor of lower corpulence in hepatitis C-infected patients: results from the ANRS CO22 Hepather cohort

Author

Barré, Tangui, Carrat, Fabrice, Ramier, Clémence, Fontaine, Hélène, Di Beo, Vincent, Bureau, Morgane, Dorival, Céline, Larrey, Dominique, Delarocque-Astagneau, Elisabeth, Mathurin, Philippe, Marcellin, Fabienne, Petrov-Sanchez, Ventzislava, Cagnot, Carole, Carrieri, Patrizia, Pol, Stanislas, Protopopescu, Camelia, Alric, Laurent, Pomes, Chloe, Zoulim, Fabien, Maynard, Marianne, Bai, Roxane, Hucault, Lucie, Bailly, François, Raffi, François, Billaud, Eric, Boutoille, David, Lefebvre, Maeva, André-Garnier, Elisabeth, Cales, Paul, Hubert, Isabelle, Lannes, Adrien, Lunel, Françoise, Boursier, Jérôme, Asselah, Tarik, Boyer, Nathalie, Giuily, Nathalie, Castelnau, Corinne, Scoazec, Giovanna, Rousseaud, Emilie, Vallet-Pichard, Anaïs, Sogni, Philippe, de Ledinghen, Victor, Foucher, Juliette, Hiriart, Jean-Baptiste, M’bouyou, Jancell, Irlès-Depé, Marie, Bourlière, Marc, Ahmed, Si Nafa Si, Oules, Valérie, Tran, Albert, Anty, Rodolphe, Gelsi, Eve, Truchi, Régine, Thabut, Dominique, Hammeche, Saloua, Moussali, Joseph, Causse, Xavier, de Dieuleveult, Barbara, Ouarani, Brahim, Labarrière, Damien, Ganne, Nathalie, Grando-Lemaire, Véronique, Nahon, Pierre, Brulé, Séverine, Ulker, Betul, Guyader, Dominique, Jezequel, Caroline, Brener, Audrey, Laligant, Anne, Rabot, Aline, Renard, Isabelle, Habersetzer, François, Baumert, Thomas, Doffoel, Michel, Mutter, Catherine, Simo-Noumbissie, Pauline, Razi, Esma, Bronowicki, Jean-Pierre, Barraud, Hélène, Bensenane, Mouni, Nani, Abdelbasset, Hassani-Nani, Sarah, Bernard, Marie-Albertine, Pageaux, Georges-Philippe, Meszaros, Magda, Metivier, Sophie, Bureau, Christophe, Morales, Thibault, Peron, Jean Marie, Robic, Marie Angèle, Decaens, Thomas, Faure, Marine, Froissart, Bruno, Hilleret, Marie-Noelle, Zarski, Jean-Pierre, Riachi, Ghassan, Goria, Odile, Paris, Fatima, Montialoux, Hélène, Leroy, Vincent, Amaddeo, Giuliana, Varaut, Anne, Simoes, Mélanie, Amzal, Rachida, Chazouillières, Olivier, Andreani, Tony, Angoulevant, Bénédicte, Chevance, Azeline, Serfaty, Lawrence, Samuel, Didier, Antonini, Teresa, Coilly, Audrey, Duclos-Vallée, Jean-Charles, Tateo, Mariagrazia, Abergel, Armand, Reymond, Maud, Brigitte, Chanteranne, Benjamin, Buchard, Muti, Léon, Geist, Claire, Conroy, Guillaume, Riffault, Raphaëlle, Rosa, Isabelle, Barrault, Camille, Costes, Laurent, Hagège, Hervé, Loustaud-Ratti, Véronique, Carrier, Paul, Debette-Gratien, Maryline, Lassailly, Guillaume, Lemaitre, Elise, Canva, Valérie, Dharancy, Sébastien, Louvet, Alexandre, Minello, Anne, Latournerie, Marianne, Bardou, Marc, Mouillot, Thomas, D’alteroche, Louis, Barbereau, Didier, Nicolas, Charlotte, Elkrief, Laure, Jaillais, Anaïs, Gournay, Jérôme, Chevalier, Caroline, Archambeaud, Isabelle, Habes, Sarah, Portal, Isabelle, Gelu-Simeon, Moana, Saillard, Eric, Lafrance, Marie-Josée, Catherine, Lucie, Chau, Frederic, Goderel, Isabelle, Lusivika-Nzinga, Clovis, Bellance, Marc-Antoine, Bellet, Jonathan, Monfalet, Priscilla, Chane-Teng, Jessica, Bijaoui, Sephora, Pannetier, Grégory, Téoulé, François, Nicol, Jérôme, Sebal, Florian, Bekhti, Rafika, Boston, Anaïs, Nailler, Laura, Le Meut, Guillaume, Diallo, Alpha, Fourati, Slim, Housset, Chantal, Bruyand, Mathias, Wittkop, Linda, Zucman-Rossi, Jessica, L’hennaff, Marianne, Sizorn, Michèle, Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Département d'hépatologie [CHU Cochin], Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Cellules Souches, Plasticité Cellulaire, Médecine Régénératrice et Immunothérapies (IRMB), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Hôpital Raymond Poincaré [Garches], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service des Maladies de l'Appareil Digestif et de la Nutrition [CHRU Lille], Hôpital Claude Huriez [Lille], CHU Lille-CHU Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), and Agence Nationale de Recherches sur le Sida et les Hépatites Virales (ANRS)

Subjects
Endocannabinoid system, Behaviors, Δ9-Tetrahydrocannabinol, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Obesity, Sciences du Vivant [q-bio]/Médecine humaine et pathologie, Chronic, Body weight, Hepatitis C, Fibrosis, Corpulence, Cannabis, Marijuana
Abstract

Background Patients with chronic hepatitis C virus (HCV) infection are at greater risk of developing metabolic disorders. Obesity is a major risk factor for these disorders, and therefore, managing body weight is crucial. Cannabis use, which is common in these patients, has been associated with lower corpulence in various populations. However, this relationship has not yet been studied in persons with chronic HCV infection. Methods Using baseline data from the French ANRS CO22 Hepather cohort, we used binary logistic and multinomial logistic regression models to test for an inverse relationship between cannabis use (former/current) and (i) central obesity (i.e., large waist circumference) and (ii) overweight and obesity (i.e., elevated body mass index (BMI)) in patients from the cohort who had chronic HCV infection. We also tested for relationships between cannabis use and both waist circumference and BMI as continuous variables, using linear regression models. Results Among the 6348 participants in the study population, 55% had central obesity, 13.7% had obesity according to their BMI, and 12.4% were current cannabis users. After multivariable adjustment, current cannabis use was associated with lower risk of central obesity (adjusted odds ratio, aOR [95% confidence interval, CI]: 0.45 [0.37–0.55]), BMI-based obesity (adjusted relative risk ratio (aRRR) [95% CI]: 0.27 [0.19–0.39]), and overweight (aRRR [95% CI]: 0.47 [0.38–0.59]). This was also true for former use, but to a lesser extent. Former and current cannabis use were inversely associated with waist circumference and BMI. Conclusions We found that former and, to a greater extent, current cannabis use were consistently associated with smaller waist circumference, lower BMI, and lower risks of overweight, obesity, and central obesity in patients with chronic HCV infection. Longitudinal studies are needed to confirm these relationships and to assess the effect of cannabis use on corpulence and liver outcomes after HCV cure. Trial registration ClinicalTrials.gov identifier: NCT01953458.

Published
2022
Full Text
View/download PDF

6. Similar 5-year HCC occurrence in Tenofovir- and Entecavir-treated HBV chronic infection in the French AFEF/ANRS CO22 Hepather cohort

Author

Pol, Stanislas, Bonnet, Delphine, Payssan-Sicart, Virginie, Pomes, Chloe, Bailly, François, Beaudoin, Marjolaine, Giboz, Dominique, Hartig-Lavie, Kerstin, Maynard, Marianne, Billaud, Eric, Boutoille, David, Cavellec, Morane, Chevalier, Caroline, Hubert, Isabelle, Goepfert, Pierre, Lannes, Adrien, Lunel, François, Boursier, Jérôme, Boyer, Nathalie, Giuily, Nathalie, Castelnau, Corinne, Scoazec, Giovanna, Chibah, Aziza, Keser, Sylvie, Bonardi, Karim, Vallet-Pichard, Anaïs, Sogni, Philippe, Foucher, Juliette, Hiriart, Jean-Baptiste, Legendre, Amandine, Chermak, Faiza, Irlès-Depé, Marie, Ahmed, Si Nafa Si, Ansaldi, Christelle, Amara, Nisserine Ben, Oules, Valérie, Dunette, Jacqueline, Anty, Rodolphe, Gelsi, Eve, Truchi, Régin, Luckina, Elena, Messaoudi, Nadia, Moussali, Joseph, Dieuleveult, Barbara De, Goin, Héloïse, Labarrière, Damien, Potier, Pascal, Grando-Lemaire, Véronique, Nahon, Pierre, Brulé, Séverin, Monard, Rym, Jezequel, Caroline, Brener, Audrey, Laligant, Anne, Rabot, Aline, Renard, Isabelle, Baumert, Thomas F, Dofföel, Michel, Mutter, Catherine, Simo-Noumbissie, Pauline, Razi, Esma, Barraud, Hélène, Bensenane, Mouni, Nani, Abdelbasset, Hassani-Nani, Sarah, Bernard, Marie-Albertine, Pageaux, Georges-Philippe, Bismuth, Michael, Caillo, Ludovic, Faure, Stéphani, Ripault, Marie Pierre, Bureau, Christophe, Launay, Sarah, Peron, Jean Marie, Robic, Marie Angèl, Tarallo, Lé, Faure, Marine, Froissart, Bruno, Hilleret, Marie-Noelle, Zarski, Jean-Pierre, Goria, Odile, Grard, Victorien, E Montialoux, Hélè, François, Muriel, Ouedraogo, Christian, Pauleau, Christelle, Varault, Anne, Andreani, Tony, E Angoulevant, Bénédic, Chevance, Azeline, Serfaty, Lawrence, Antonini, Teresa, Coilly, Audrey, Vallée, Jean-Charles Duclos, Tateo, Mariagrazia, Bonny, Corinne, Brigitte, Chanteranne, Lamblin, Géraldin, Muti, Léo, Babouri, Abdenour, Filipe, Virginie, Barrault, Camille, Costes, Laurent, Merbah, Soraya, Carrier, Paul, Debette-Gratien, Maryline, Jacques, Jérémie, Lassailly, Guillaume, Artu, Florent, Canva, Valérie, Dharancy, Sébastie, Louvet, Alexandre, Latournerie, Marianne, Bardou, Marc, Mouillot, Thomas, Bacq, Yannick, Barbereau, Didier, Nicolas, Charlotte, Archambeaud, Isabelle, Habes, Sarah, Botta-Fridlund, Danièl, Saillard, Eric, Lafrance, Marie-José, Nzinga, Clovis Luzivika, Dorival, Céline, Zoulim, Fabien, Cagnot, Carole, Decaens, Thomas, Thabut, Dominique, Asselah, Tarik, Mathurin, Philippe, Ganne, Nathalie, Samuel, Didier, Habersetzer, Françoi, Bronowicki, Jean-Pierre, Guyader, Dominique, Rosa, Isabelle, Leroy, Vincent, Chazouilleres, Olivier, Ledinghen, Victor De, Bourliere, Marc, Causse, Xavier, Cales, Paul, Metivier, Sophie, Loustaud-Ratti, Véroniqu, Abergel, Armand, Fontaine, Hélène, Carrat, Fabrice, Département d'hépatologie [CHU Cochin], Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Physiopathologie du système immunitaire (Inserm U1223), Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)

Subjects
MESH: Antiviral Agents, MESH: Guanine, MESH: Hepatitis B virus, MESH: Humans, MESH: Tenofovir, MESH: Hepatitis B, Chronic, MESH: Liver Neoplasms, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, MESH: Carcinoma, Hepatocellular, MESH: Prospective Studies, MESH: Treatment Outcome
Abstract

International audience; Background: Chronic hepatitis B virus (HBV) infection results in a high risk of cirrhosis and its complications, cirrhosis decompensation (DC), hepatocellular carcinoma (HCC), liver transplantation (LT), death or any of these outcomes (composite endpoint [CE]). Nucleos(t)ide analogues (NUCs) such as tenofovir or entecavir are associated with a reduction in these complications.Aim: To compare the impact of tenofovir and entecavir on these outcomes in patients treated for HBV infection and included in the prospective Hepather cohort.Methods: All patients with HBV infection who had received tenofovir or entecavir for more than 6 months at or after entry in the ANRS CO22 cohort were selected. Patients with HDV and HCV co-infection or prior liver event were excluded. Incidence rates of events were compared using inverse probability of treatment weighting (IPW).Results: The cohort included 1800 patients (986 tenofovir and 814 entecavir). Median follow-up was 4.2 years. The incidences of HCC, DC, LT, ACD, LRD and CE were not different between tenofovir- (1.8 (0.9; 3.2), 0.6 (0.2; 1.6), 0.2 (0.0; 0.8), 1.7 (0.8; 3.0), 0.8 (0.2, 1.8) and 4.1 (3.0; 5.4) per 1000 person-years) and entecavir-treated patients (1.6 (0.7; 3.0), 0.7 (0.2; 1.8), 0.2 (0.0; 1.0), 3.0 (1.7, 4.8), 0.5 (0.1; 1.5) and 5.0 (3.3; 7.2)) per 1000 person-years, respectively.Conclusion: The risk of liver-related events or death was not different between tenofovir- and entecavir-treated patients in this large prospective cohort of predominantly non-cirrhotic French patients.Trial registration number: NCT019553458.

Published
2021
Full Text
View/download PDF

7. Cannabis Use Is Inversely Associated with Overweight and Obesity in Hepatitis B Virus-Infected Patients (ANRS CO22 Hepather Cohort)

Author

Barré, Tangui, Pol, Stanislas, Ramier, Clémence, Di Beo, Vincent, Carrat, Fabrice, Bureau, Morgane, Bourlière, Marc, Dorival, Céline, Serfaty, Lawrence, Asselah, Tarik, Boursier, Jérôme, Marcellin, Fabienne, Carrieri, Patrizia, Fontaine, Hélène, Protopopescu, Camelia, Alric, Laurent, Bonnet, Delphine, Payssan-Sicart, Virginie, Pomes, Chloe, Zoulim, Fabien, Maynard, Marianne, Bai, Roxane, Hucault, Lucie, Bailly, François, Raffi, François, Billaud, Eric, Boutoille, David, Lefebvre, Maeva, André-Garnier, Elisabeth, Cales, Paul, Hubert, Isabelle, Lannes, Adrien, Lunel, Françoise, Boyer, Nathalie, Giuily, Nathalie, Castelnau, Corinne, Scoazec, Giovanna, Rousseaud, Emilie, Vallet-Pichard, Anaïs, Sogni, Philippe, Ledinghen, Victor De, Foucher, Juliette, Hiriart, Jean-Baptiste, M'Bouyou, Jancell, Irlès-Depé, Marie, Si Ahmed, Si Nafa, Oules, Valérie, Tran, Albert, Anty, Rodolphe, Gelsi, Eve, Truchi, Régine, Thabut, Dominique, Hammeche, Saloua, Moussali, Joseph, Causse, Xavier, Dieuleveult, Barbara De, Ouarani, Brahim, Labarrière, Damien, Ganne, Nathalie, Grando-Lemaire, Véronique, Nahon, Pierre, Brulé, Séverine, Ulker, Betul, Guyader, Dominique, Jezequel, Caroline, Brener, Audrey, Laligant, Anne, Rabot, Aline, Renard, Isabelle, Habersetzer, François, Baumert, Thomas, Doffoel, Michel, Mutter, Catherine, Simo-Noumbissie, Pauline, Razi, Esma, Bronowicki, Jean-Pierre, Barraud, Hélène, Bensenane, Mouni, Nani, Abdelbasset, Hassani-Nani, Sarah, Bernard, Marie-Albertine, Pageaux, Georges-Philippe, Larrey, Dominique, Meszaros, Magda, Metivier, Sophie, Bureau, Christophe, Morales, Thibault, Peron, Jean Marie, Robic, Marie Angèle, Decaens, Thomas, Faure, Marine, Froissart, Bruno, Hilleret, Marie-Noelle, Zarski, Jean-Pierre, Riachi, Ghassan, Goria, Odile, Paris, Fatima, Montialoux, Hélène, Leroy, Vincent, Amaddeo, Giuliana, Varaut, Anne, Simoes, Mélanie, Amzal, Rachida, Chazouillières, Olivier, Andreani, Tony, Angoulevant, Bénédicte, Chevance, Azeline, Samuel, Didier, Antonini, Teresa, Coilly, Audrey, Duclos Vallée, Jean-Charles, Tateo, Mariagrazia, Abergel, Armand, Reymond, Maud, Brigitte, Chanteranne, Benjamin, Buchard, Muti, Léon, Geist, Claire, Conroy, Guillaume, Riffault, Raphaëlle, Rosa, Isabelle, Barrault, Camille, Costes, Laurent, Hagège, Hervé, Loustaud-Ratti, Véronique, Carrier, Paul, Debette-Gratien, Maryline, Mathurin, Philippe, Lassailly, Guillaume, Lemaitre, Elise, Canva, Valérie, Dharancy, Sébastien, Louvet, Alexandre, Minello, Anne, Latournerie, Marianne, Bardou, Marc, Mouillot, Thomas, d'Alteroche, Louis, Barbereau, Didier, Nicolas, Charlotte, Elkrief, Laure, Jaillais, Anaïs, Gournay, Jérôme, Chevalier, Caroline, Archambeaud, Isabelle, Habes, Sarah, Portal, Isabelle, Gelu-Simeon, Moana, Saillard, Eric, Lafrance, Marie-Josée, Catherine, Lucie, Nutrition, obésité et risque thrombotique (NORT), Institut National de la Recherche Agronomique (INRA)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d'hépatologie médicale [CHU Cochin], Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), ESIM - Déterminants Sociaux de la Santé et du Recours aux Soins (DS3), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d'hépato-gastro-entérologie, Assistance Publique - Hôpitaux de Marseille (APHM), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Hôpital de Hautepierre [Strasbourg], Service d’Hépatologie [Hôpital Beaujon], Hôpital Beaujon [AP-HP], Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Pierre et Marie Curie - Paris 6 (UPMC), and BOURGEAIS, Véronique

Subjects
Hepatitis B virus, medicine.medical_specialty, Cirrhosis, [SDV]Life Sciences [q-bio], Aucun, Overweight, medicine.disease_cause, Virus, 03 medical and health sciences, Hepatitis B, Chronic, 0302 clinical medicine, Internal medicine, medicine, Humans, Pharmacology (medical), Obesity, ComputingMilieux_MISCELLANEOUS, Cannabis, 030304 developmental biology, Pharmacology, 0303 health sciences, biology, Cannabinoids, business.industry, Liver Neoplasms, Hepatitis B, biology.organism_classification, medicine.disease, digestive system diseases, 3. Good health, [SDV] Life Sciences [q-bio], Complementary and alternative medicine, Hepatocellular carcinoma, Cohort, cannabis, obesity, overweight, socioeconomic status, 030211 gastroenterology & hepatology, medicine.symptom, business
Abstract

International audience; Background: Chronic hepatitis B virus (HBV) infection may evolve into cirrhosis and hepatocellular carcinoma, and this progression may be accelerated by specific risk factors, including overweight and obesity. Although evidence for a protective effect of cannabis use on elevated body weight has been found for other populations, no data are available for HBV-infected patients.Aims: We aimed to identify risk factors (including cannabis use) for overweight and obesity in patients with HBV chronic infection.Methods: Using baseline data from the French ANRS CO22 Hepather cohort, we performed two separate analyses, one using “central obesity” (based on waist circumference) and the other “overweight” and “obesity” (based on body mass index) as outcomes. Logistic and multinomial regressions were used to model central obesity and overweight/obesity, respectively.Results: Among the 3706 patients in the study population, 50.8% had central obesity, 34.7% overweight, and 14.4% obesity. After multivariable adjustment, current cannabis use was associated with a 59% lower risk of central obesity compared with no lifetime use (adjusted odds ratio [95% CI]: 0.41 [0.24 to 0.70]). It was also associated with a 54% and 84% lower risk of overweight (adjusted relative risk ratio [95% CI]: 0.46 [0.27 to 0.76]) and obesity (0.16 [0.04 to 0.67]), respectively.Conclusions: Cannabis use was associated with lower risks of overweight and obesity in patients with HBV chronic infection. Future studies should test whether these potential benefits of cannabis and cannabinoid use translate into reduced liver disease progression in this high-risk population.

Published
2021
Full Text
View/download PDF

9. Absence of impact of direct acting antivirals for hepatitis C virus on recurrent hepatocellular carcinoma tumor growth in the AFEF/ANRS CO22 Hepather cohort

Author

Vallet-Pichard, Anais, primary, Correas, Jean-Michel, additional, Dorival, Celine, additional, Zoulim, Fabien, additional, Tran, Albert, additional, Bourlière, Marc, additional, Calès, Paul, additional, Guyader, Dominique, additional, Bronowicki, Jean-Pierre, additional, Larrey, Dominique, additional, Hezode, Christophe, additional, Loustaud-Ratti, Veronique, additional, Gournay, Jerome, additional, de Ledinghen, Victor, additional, Asselah, Tarik, additional, Ganne, Nathalie, additional, Metivier, Sophie, additional, Chazouillères, Olivier, additional, Leroy, Vincent, additional, Rosa, Isabelle, additional, Samuel, Didier, additional, Mathurin, Philippe, additional, Cagnot, Carole, additional, Fontaine, Helene, additional, Carrat, Fabrice, additional, Pol, Stanislas, additional, Bonnet, Delphine, additional, Payssan-Sicart, Virginie, additional, Pomes, Chloe, additional, Bailly, François, additional, Beaudoin, Marjolaine, additional, Giboz, Dominique, additional, Hartig-Lavie, Kerstin, additional, Maynard, Marianne, additional, Billaud, Eric, additional, Boutoille, David, additional, Cavellec, Morane, additional, Cheraud-Carpentier, Marjorie, additional, Hubert, Isabelle, additional, Benhida, Jaouad, additional, Lannes, Adrien, additional, Lunel, Françoise, additional, Oberti, Frédéric, additional, Boyer, Nathalie, additional, Giuily, Nathalie, additional, Castelnau, Corinne, additional, Scoazec, Giovanna, additional, Chibah, Aziza, additional, Keser, Sylvie, additional, Bonardi, Karim, additional, Vallet-Pichard, Anaïs, additional, Sogni, Philippe, additional, Foucher, Juliette, additional, Hiriart, Jean-Baptiste, additional, Wilson, Amy, additional, Shili, Sarah, additional, Chermak, Faiza, additional, Ansaldi, Christelle, additional, Amara, Nisserine Ben, additional, Chouquet, Laëtitia, additional, De Luca, Emilie, additional, Oules, Valérie, additional, Anty, Rodolphe, additional, Gelsi, Eve, additional, Truchi, Régine, additional, Luckina, Elena, additional, Messaoudi, Nadia, additional, Moussali, Joseph, additional, De Dieuleveult, Barbara, additional, Labarriere, Damien, additional, Poter, Pascal, additional, Ahmed, Si Nafa Si, additional, Grando-Lemaire, Véronique, additional, Nahon, Pierre, additional, Bourcier, Valérie, additional, Brulé, Séverine, additional, Stalhberger, Thomas, additional, Jezequel, Caroline, additional, Brener, Audrey, additional, Laligant, Anne, additional, Rabot, Aline, additional, Renard, Isabelle, additional, Baumert, Thomas F., additional, Dofföel, Michel, additional, Mutter, Catherine, additional, Simo-Noumbissie, Pauline, additional, Razi, Esma, additional, Barraud, Hélène, additional, Bensenane, Mouni, additional, Nani, Abdelbasset, additional, Hassani-Nani, Sarah, additional, Bernard, Marie-Albertine, additional, Pageaux, Georges-Philippe, additional, Bismuth, Michael, additional, Caillo, Ludovic, additional, Faure, Stéphanie, additional, Ripault, Marie-Pierre, additional, Bureau, Christophe, additional, Peron, Jean Marie, additional, Robic, Marie-Angèle, additional, Tarallo, Léa, additional, Faure, Marine, additional, Froissart, Bruno, additional, Hilleret, Marie-Noelle, additional, Zarski, Jean-Pierre, additional, Goria, Odile, additional, Grard, Victorien, additional, Montialoux, Hélène, additional, François, Muriel, additional, Ouedraogo, Christian, additional, Pauleau, Christelle, additional, Varault, Anne, additional, Andreani, Tony, additional, Angoulevant, Bénédicte, additional, Chevance, Azeline, additional, Serfaty, Lawrence, additional, Antonini, Teresa, additional, Coilly, Audrey, additional, Vallée, Jean-Charles Duclos, additional, Tateo, Mariagrazia, additional, Bonny, Corinne, additional, Brigitte, Chanteranne, additional, Lamblin, Géraldine, additional, Muti, Léon, additional, Babouri, Abdenour, additional, Filipe, Virginie, additional, Barrault, Camille, additional, Costes, Laurent, additional, Hagège, Hervé, additional, Merbah, Soraya, additional, Carrier, Paul, additional, Debette-Gratien, Maryline, additional, Jacques, Jérémie, additional, Lassailly, Guillaume, additional, Artu, Florent, additional, Canva, Valérie, additional, Dharancy, Sébastien, additional, Louvet, Alexandre, additional, Latournerie, Marianne, additional, Bardou, Marc, additional, Mouillot, Thomas, additional, Bacq, Yannick, additional, Barbereau, Didier, additional, Nicolas, Charlotte, additional, Chevalier, Caroline, additional, Archambeaud, Isabelle, additional, Habes, Sarah, additional, Botta-Fridlund, Danièle, additional, Saillard, Eric, additional, and Lafrance, Marie-Josée, additional

Published
2021
Full Text
View/download PDF

14. THU-142-Sofosbuvir + velpatasvir + voxilaprevir in DAA failure patients with cirrhosis: Final results of the French compassionate use program

Author

Hezode, Christophe, primary, Guyader, Dominique, additional, Nguyen-Khac, Eric, additional, Larrey, Dominique, additional, Truchi, Régine, additional, Martino, Vincent Di, additional, Calmus, Yvon, additional, Franza, Anne Minello, additional, Giuily, Nathalie, additional, Mokhtari, Saadi, additional, Hartig, Kerstin, additional, Cotte, Laurent, additional, Ribard, Didier, additional, Valantin, Marc-Antoine, additional, Bonyhay, Luminita, additional, Antoni, Michel, additional, Bronowicki, Jean-Pierre, additional, Combis, Jean-Marc, additional, Pilette, Christophe, additional, Zamora, Christophe, additional, Domitille, Erard, additional, Arpurt, Jean-Pierre, additional, Renou, Christophe, additional, Bourliere, Marc, additional, Grando, Véronique, additional, and Canva, Valérie, additional

Published
2019
Full Text
View/download PDF

18. Efficacy and safety of sofosbuvir-based therapies in patients with advanced liver disease in a real-life cohort

Author

Kutala,Blaise K, Mouri,Feryel, Castelnau,Corinne, Bouton,Valerie, Giuily,Nathalie, Boyer,Nathalie, Asselah,Tarik, Marcellin,Patrick, Kutala,Blaise K, Mouri,Feryel, Castelnau,Corinne, Bouton,Valerie, Giuily,Nathalie, Boyer,Nathalie, Asselah,Tarik, and Marcellin,Patrick

Abstract

Blaise K Kutala,1,2 Feryel Mouri,1 Corinne Castelnau,1 Valerie Bouton,1 Nathalie Giuily,1 Nathalie Boyer,1 Tarik Asselah,1,2 Patrick Marcellin1,2 1Service d’hépatologie, Hopital Beaujon-APHP, 2INSERM – University of Paris Diderot, Paris, France Background: The combination of sofosbuvir (SOF) with ribavirin (RBV) or daclatasvir (DCV) or simeprevir (SIM) for the treatment of patients infected by chronic hepatitis C (CHC) have led to significantly increased rates of sustained virological response (SVR). However, there is only limited data regarding factors associated with treatment failure in a “real-life” cohort. Patients and methods: Consecutive treatment-naive and treatment-experienced patients F3–F4 were treated with SOF-based interferon-free therapy in our hospital from November 2013 to July 2015. The primary endpoint was the proportion of patients with sustained virological response 12 weeks after cessation of therapy (SVR12). Results: A total of 167 treatment-naive and 207 treatment-experienced patients were treated and followed up for 2 years (n=383). Overall, 71% were men; among them, 54% had cirrhosis and the median age was 53 years. SVR12 was achieved by 82% of the patients receiving SOF+RBV, 92% receiving SOF+DCV, and 79% receiving SOF+SIM. Metavir F4 and albumin serum were found as independent risk factors associated with treatment failure in groups receiving SOF+RBV (p=0.008 and p=0.001), SOF+DCV (p=0.038 and p=0.043), and SOF+SIM±RBV (p=0.014 and p=0.017), respectively. The most common adverse events were fatigue, nausea, headache, and anemia. Three patients discontinued the treatment due to an adverse event. Conclusion: These findings suggest that 12-week SOF-based regimen plus RBV or DCV or SIM is an efficacious and well-tolerated treatment in CHC patients with fibrosis stage F3–F4. Patients, who display risk factors for cirrhosis, should be referred to an experienced vir

Published
2017

19. Éducation thérapeutique et hépatites: une nouvelle écologie du patient, «le parcours de soin». Un exemple avec le réseau REVHEPAT.

Author

Boyer, Nathalie, Aurières, Christine, Monnier, Béatrice, Bouton, Valérie, Cattan, Laurent, De Freitas, Cecilia, Giuily, Nathalie, Castelnau, Corinne, Sitruk, Véronique, Abazid, Malek, Asselah, Tarik, Marcellin, Patrick, and Kerjean, Nathalie Pons

Abstract

Copyright of Hépato-Gastro & Oncologie Digestive is the property of John Libbey Eurotext Ltd. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2017
Full Text
View/download PDF

20. Direct comparison of diagnostic performance of transient elastography in patients with chronic hepatitis B and chronic hepatitis C

Author

Cardoso, Ana-Carolina, primary, Carvalho-Filho, Roberto J., additional, Stern, Christiane, additional, Dipumpo, Alexandrine, additional, Giuily, Nathalie, additional, Ripault, Marie-Pierre, additional, Asselah, Tarik, additional, Boyer, Nathalie, additional, Lada, Olivier, additional, Castelnau, Corinne, additional, Martinot-Peignoux, Michelle, additional, Valla, Dominique-Charles, additional, Bedossa, Pierre, additional, and Marcellin, Patrick, additional

Published
2011
Full Text
View/download PDF

21. Virological response at 4 weeks to predict outcome of hepatitis C treatment with pegylated interferon and ribavirin

Author

Martinot-Peignoux, Michelle, primary, Maylin, Sarah, additional, Moucari, Rami, additional, Ripault, Marie-Pierre, additional, Boyer, Nathalie, additional, Cardoso, Ana-Carolina, additional, Giuily, Nathalie, additional, Castelnau, Corinne, additional, Pouteau, Michèle, additional, Stern, Christiane, additional, Aupérin, Anne, additional, Bedossa, Pierre, additional, Asselah, Tarik, additional, and Marcellin, Patrick, additional

Published
2008
Full Text
View/download PDF

23. Virological response at 4 weeks to predict outcome of hepatitis C treatment with pegylated interferon and ribavirin

Author

Martinot-Peignoux, Michelle, Maylin, Sarah, Moucari, Rami, Ripault, Marie-Pierre, Boyer, Nathalie, Cardoso, Ana-Carolina, Giuily, Nathalie, Castelnau, Corinne, Pouteau, Michèle, Stern, Christiane, Aupérin, Anne, Bedossa, Pierre, Asselah, Tarik, and Marcellin, Patrick

Abstract

Background Viral kinetics during therapy provides information on how to individualize treatment. To determine the benefit of assessing positive predictive values (PPVs) and negative predictive values (NPVs) of rapid virological responses (RVRs) and early virological responses (EVRs), on-treatment outcomes in chronic hepatitis C patients were examined.Methods A total of 408 patients (221 treatment-naive) treated with pegylated interferon-a2b and ribavirin were included. Hepatitis C virus (HCV) RNA was measured at baseline, 4 weeks and 12 weeks. RVR was defined as undetectable HCV RNA at 4 weeks and EVR as =2 log10decrease in HCV RNA at 12 weeks. The additive value of RVR on predicting sustained virological response (SVR) was assessed with receiver operating characteristic (ROC) curves.Results SVR, RVR and EVR were observed in 46%, 23% and 78% of patients, respectively. PPVs of RVR were 96%, 100% and 100% in treatment-naive patients, relapsers and non-responders, respectively. NPVs of failure to achieve EVR were 97%, 75% and 91%, in treatment- naive patients, relapsers and non-responders, respectively. At 4 weeks, patients with RVR had the highest probability to achieve SVR (odds ratio 44.98 in the entire population and 32.95 in treatment-naive patients). ROC curves showed the area under the ROC curve to be 0.758 versus 0.832 in the entire population and 0.795 versus 0.858 in treatment-naive patients at baseline versus week 4, respectively.Conclusions RVR is a strong predictor of SVR (PPV>96%) and failure to achieve EVR is a strong predictor of non-SVR (NPV>75%), independent of patients’ pretreatment status. Added to baseline characteristics, RVR increased the accuracy to predict SVR. The combination of RVR and EVR provided complementary information, and thus provides a key opportunity to individualize treatment and improve the benefit/risk ratio of therapy.

Published
2009
Full Text
View/download PDF

24. Efficacy and safety of sofosbuvir-based therapies in patients with advanced liver disease in a real-life cohort.

Author

Kutala BK, Mouri F, Castelnau C, Bouton V, Giuily N, Boyer N, Asselah T, and Marcellin P

Abstract

Background: The combination of sofosbuvir (SOF) with ribavirin (RBV) or daclatasvir (DCV) or simeprevir (SIM) for the treatment of patients infected by chronic hepatitis C (CHC) have led to significantly increased rates of sustained virological response (SVR). However, there is only limited data regarding factors associated with treatment failure in a "real-life" cohort., Patients and Methods: Consecutive treatment-naive and treatment-experienced patients F3-F4 were treated with SOF-based interferon-free therapy in our hospital from November 2013 to July 2015. The primary endpoint was the proportion of patients with sustained virological response 12 weeks after cessation of therapy (SVR12)., Results: A total of 167 treatment-naive and 207 treatment-experienced patients were treated and followed up for 2 years (n=383). Overall, 71% were men; among them, 54% had cirrhosis and the median age was 53 years. SVR12 was achieved by 82% of the patients receiving SOF+RBV, 92% receiving SOF+DCV, and 79% receiving SOF+SIM. Metavir F4 and albumin serum were found as independent risk factors associated with treatment failure in groups receiving SOF+RBV ( p =0.008 and p =0.001), SOF+DCV ( p =0.038 and p =0.043), and SOF+SIM±RBV ( p =0.014 and p =0.017), respectively. The most common adverse events were fatigue, nausea, headache, and anemia. Three patients discontinued the treatment due to an adverse event., Conclusion: These findings suggest that 12-week SOF-based regimen plus RBV or DCV or SIM is an efficacious and well-tolerated treatment in CHC patients with fibrosis stage F3-F4. Patients, who display risk factors for cirrhosis, should be referred to an experienced viral hepatitis center., Competing Interests: Disclosure Blaise K Kutala, Feryel Mouri, Corinne Castelnau, Valerie Bouton, Nathalie Giuily, and Nathalie Boyer certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge, or beliefs) in the subject matter or materials discussed in this manuscript. Tarik Asselah and Patrick Marcellin report the following details of affiliation or involvement in an organization or entity with a non-financial interest in the subject matter or materials discussed in this manuscript. They are speaking and teaching and attending advisor commitee for Roche, Novartis, Bayer, BMS, Gilead Science, Merck, Janssen, and AbbVie. The authors report no other conflicts of interest in this work.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results